A WORD FROM OUR CHIEF SCIENTIFIC OFFICER

We are in the midst of a productive season in the FAPI space.  Our Phase 3 [18F]FAPI-74 diagnostic studies, FAPI-GO (FAPI in Gastroesophageal Oncology, NCT0721770466) and FAPI-PRO (FAPI in Precision Imaging of Pancreatic Cancer, NCT0721771755) are well underway with 11 sites activated, as we continue activating additional sites and enrolling patients.

Education is a key component of our clinical development efforts. Below is a list of my recent and upcoming virtual outreach activities:

  • Gave a 3-minute talk on our FAP targeting journey to Phase 3 trials (Targeted Radiotherapeutics MicroSummit, April 28)
  • Participated in an expert panel on “FAP Imaging & Theranostics: How to Cross the Finish Line” (organized by Perceptive, May 5)
  • (this week, May 13!) Present a webinar, “Clinical Development Progress of FAP Targeting Radioligands”; more details and registration are available here1313.

SOFIE is hosting our 5th Satellite Symposium77, “FAP in Focus-Oncology and Horizons Beyond Cancer” at the annual SNMMI meeting on Sunday, May 31, 6:30 pm. We’ll also be at the SOFIE Booth (1335) if you have any questions.  We look forward to seeing you in sunny Los Angeles!

If you’d like to reach us, please send an email to fapiprogram@sofie.com

– Sherly Mosessian, Ph.D., Chief Scientific Officer

Sherly Mosessian, Ph.D.

[18F]FAPI-74 CLINICAL DEVELOPMENT UPDATE

FAPI ON THE MOVE

For the latest FAPI updates, visit SOFIE’s LinkedIn page!

PUBLICATION HIGHLIGHTS

Each newsletter will feature recent FAPI publications.

Fully Automated [18F]AlF Radiolabeling Using a Microdroplet Reactor Platform

Chem Eng J. 2026 Jan 

A 3D co-culture model with fibroblast-restricted FAP expression for cancer therapy using [212Pb]Pb-FAPI-46

EJNMMI Radiopharm Chem. 2026 Apr 18

Safety of [68Ga]Ga-FAPI-46 PET/CT including hemodynamic measurements and patient-reported outcomes in cancer patients

Clin Physiol Funct Imaging. 2026 May

FAPI OUTREACH PROGRAM

Join us in advancing the frontier of molecular imaging through the FAPI Outreach Program

SOFIE is continuing to accept applications for our FAPI Outreach Program. This program aims to raise awareness and foster collaboration in the field of molecular imaging, specifically focusing on Fibroblast Activation Protein Inhibitor (FAPI) studies. This program seeks to engage with healthcare professionals, researchers, and the broader community to share knowledge, advancements, and the potential impact of FAPI in diagnostic and therapeutic applications.

*GE Healthcare licensed products and regions are accepting new applications.

Copyright 2026 SOFIE CO. / ITHERANOSTICS INC. (21000 Atlantic Blvd. Suite 730  Dulles, VA  20166) all rights reserved.  The text or images in the newsletter may not be copied or distributed without prior permission of SOFIE. The SOFIE logo is a registered trademark of SOFIE CO. / ITHERANOSTICS INC., in the United States and/or other countries. All other trademarks referenced herein are the property of their respective owners. You have received this mail because you have subscribed for a newsletter at www.sofie.com or because you are an existing client or partner of SOFIE. If you no longer wish to receive these emails, click here to opt out.  This newsletter is meant to serve as an informational document as a service to our customers. The content or material provided is for informational purposes only and should and should not be construed as medical, legal, financial, investment, or other professional advice or opinion. SOFIE does not offer personalized medical advice or patient-specific treatment advice.